MNX1 and prostate cancer: Recently, a growing number of studies suggested that MNX1-AS1 was aberrantly expressed in diverse malignancies, including cholangiocarcinoma [13], esophagus cancer [14], breast carcinoma [15–17], gastric carcinoma [12,18,19], bladder carcinoma [20], ovarian carcinoma [21,22], cervical cancer [23], osteosarcoma [24,25], laryngeal cancer [26], lung cancer [27–29], prostate cancer [30], hepatocellular carcinoma [15], glioblastoma [31] and colon adenocarcinoma [32].